CASI Pharmaceuticals Inc CASI:NASDAQ

Last Price$0.35NASDAQ Previous Close - Last Trade as of 4:00PM ET 5/13/22
NASDAQ 15-minute delayed Bid/Ask Quotes
Today's Change0(0.00%)
Bid (Size)$0.33 (1)
Ask (Size)$0.35 (17)
Day Low / HighN/A - N/A
Volume13.8 K

View Pharmaceuticals: Major IndustryPeer Comparison as of 05/13/2022


CASI Pharmaceuticals Inc ( NASDAQ )

Price: $0.35
Change: +0.04 (11.66%)
Volume: 13.8 K
4:00PM ET 5/13/2022

AIM ImmunoTech Inc ( NYSE MKT LLC )

Price: $0.99
Change: +0.03 (2.92%)
Volume: 2.5 K
8:00PM ET 5/13/2022

Infinity Pharmaceuticals Inc ( NASDAQ )

Price: $0.54
Change: +0.02 (3.33%)
Volume: 115.00
4:00PM ET 5/13/2022

Corvus Pharmaceuticals Inc ( NASDAQ )

Price: $1.04
Change: 0.00 (0.00%)
Volume: 494.9 K
4:00PM ET 5/13/2022

Beyondspring Inc ( NASDAQ )

Price: $1.25
Change: -0.05 (3.85%)
Volume: 1.00
4:00PM ET 5/13/2022

Read more news Recent News

-- Earnings Flash (CASI) CASI PHARMACEUTICALS Reports Q1 Revenue $9M, vs. Street Est of $9.24M
7:02AM ET 5/12/2022 MT Newswires


CASI Pharmaceuticals Evaluating Options to Remain Listed in US
7:29AM ET 4/01/2022 MT Newswires

CASI Pharmaceuticals (CASI) said Friday it is considering strategic options to meet the requirements of the Holding Foreign Companies Accountable Act, or...

CASI Pharmaceuticals Renews Distribution Agreement for EVOMELA in China
7:18AM ET 3/04/2022 MT Newswires

CASI Pharmaceuticals (CASI) said Friday that it has renewed the exclusive agreement with China Resources Pharmaceutical Commercial Group International...

CASI Pharmaceuticals Says BioInvent Secured US Orphan Drug Designation for Follicular Lymphoma Treatment
7:46AM ET 1/20/2022 MT Newswires

CASI Pharmaceuticals (CASI) said Thursday that the US Food and Drug Administration has granted its partner BioInvent International with an orphan drug...

Company Profile

Business DescriptionCASI Pharmaceuticals, Inc. is a biopharmaceutical company, which is focused on the acquisition, development and commercialization of therapeutics addressing cancer and other unmet medical needs. The company develops and commercializes the oncology drugs and drug candidates in China, Taiwan, Hong Kong, and Macau. Its products include Zevalin, Evomela, and Marqibo. The company was founded in 1991 and is headquartered in Rockville, MD. View company web site for more details
Address9620 Medical Center Drive
Rockville, Maryland 20850
Number of Employees125
Recent SEC Filing05/12/20228-K
Executive Chairman & Chief Executive OfficerWei-Wu He
President & Chief Financial OfficerWei Zhang
Chief Medical Officer & Executive Vice PresidentAlexander A. Zukiwski
Chief Business Development OfficerJames E. Goldschmidt

Company Highlights

Price Open$0.33
Previous Close$0.35
52 Week Range$0.31 - 1.78
Market Capitalization$47.4 M
Shares Outstanding136.1 M
SectorHealth Technology
IndustryPharmaceuticals: Major
Next Earnings Announcement08/11/2022

Options Summary

Call Open Interest (1d)*
Put Open Interest (1d)*
Call Volume (1d)*
Put Volume (1d)*
Put Call Open Interest Ratio (1d)*
Put Call Volume Ratio (1d)*
* Data delayed by up to 15 minutes

View all fundamentalsFundamentals

Price / EarningsN/A
Earnings per Share-$0.26
Beta vs. S&P 500N/A
Net Profit Margin-122.10%
Return on Equity-40.07%

Analyst Ratings as of 02/17/2022

Consensus RecommendationConsensus Icon
Powered by Factset